Oxford Immunotec Global PLC (NASDAQ:OXFD) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $8.30 and last traded at $8.38, with a volume of 49,268 shares traded. The stock had previously closed at $8.68.

Several research analysts have commented on OXFD shares. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a research report on Monday, June 27th. Finally, Zacks Investment Research lowered Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th.

The stock’s 50-day moving average price is $8.92 and its 200-day moving average price is $9.90. The company’s market cap is $189.10 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). During the same period in the previous year, the company earned ($0.31) EPS. The company earned $17.10 million during the quarter, compared to analysts’ expectations of $16.96 million. Oxford Immunotec Global PLC’s quarterly revenue was up 23.9% on a year-over-year basis. On average, equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.28) EPS for the current year.

An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. boosted its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned 4.74% of Oxford Immunotec Global PLC worth $12,293,000 as of its most recent filing with the SEC.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.